Platform|API|Archive|Contact
Humanexa SignalsPharmaceutical Intelligence
Subscribe
Signals
Regulatory
  • FDA
  • EMA
  • MHRA
  • PMDA
  • Health Canada
Clinical
  • Phase I
  • Phase II
  • Phase III
  • Readouts
  • Enrollment Signals
Competitive
  • Pipeline Tracking
  • Company Moves
  • Asset Intelligence
  • Landscape Reports
Markets
  • Pricing
  • Access
  • Commercial
  • Launch Tracking
M&A Watch
  • Licensing
  • Acquisitions
  • Partnerships
  • Capital Raises
StrategyCatalystsPricing
Humanexa Signals

Data-driven pharmaceutical intelligence for biotech investors, pharma operators, consultants, and intelligence teams.

Powered by Humanexa

Categories

  • Regulatory
  • Clinical
  • Competitive
  • Markets
  • M&A Watch
  • Strategy
  • Catalyst Tracker

Company

  • Pricing
  • Partner with us
  • Subscribe
  • Contact
  • Privacy

Subscribe to Humanexa Signals

Weekly intelligence for pharma decision-makers.

No paywall. No spam. Unsubscribe anytime.

© 2026 Humanexa Signals. All rights reserved.

Intelligence powered by the Humanexa engine.

Indication

Peripheral Arterial Disease

Clinical and regulatory intelligence for Peripheral Arterial Disease with 2 indexed intelligence signals across regulatory, clinical, competitive, and market developments.

Signals
2
Catalysts
0
Assets
1

Relevant assets

Everolimus →

Relevant companies

No related entities indexed yet.

Recent signals(2)

ClinicalJuly 6, 2026

Study on Predictors of Major Adverse Limb Events After Iliac Stenting

A real-world cohort study will evaluate predictors of major adverse limb events after endovascular iliac artery stenting.

ClinicalJuly 3, 2026

Cook Research initiates RCT for Evero DCB in PAD treatment

The Evero drug-coated balloon is being evaluated for long-term safety and effectiveness against paclitaxel DCBs in PAD.

Upcoming catalysts

No catalysts indexed for this entity yet.

Therapeutic areas

Cardiology →
Cardiovascular →
Peripheral Arterial Disease →

Newsletter

Get signals before the market moves

Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.

No paywall. No spam. Unsubscribe anytime.